1921
Volume 101, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Mucosal leishmaniasis (ML) is characterized by high production of inflammatory cytokines. Administration of pentoxifylline (PTX), an inhibitor of TNF-alpha, with pentavalent antimony (Sb), has been successfully used as alternative treatment for refractory ML. Our study aims to investigate the in situ cellular response underlying the effectiveness of this therapy, by evaluating the intensity of the inflammatory infiltrate, cellular composition, and expression of cytokines and granzyme A in lesions from ML before and after treatment with Sb alone or in combination with PTX. Our data showed no differences in the intensity of inflammatory infiltrate comparing before and after treatment, and comparing between different treatments. However, although the number and frequency of CD4 and CD8 cells were not different before and after treatments or comparing different treatments, frequency of CD68 cells decreased after treatment with Sb + PTX, but not with Sb. This was due to a reduction in CD68 TNF-alpha and not in CD68 IL-10 cells. The frequency of TNF-alpha cells was correlated with the intensity of the inflammatory infiltrate before treatment, but this correlation was lost after treatment with Sb + PTX. Although the total expression of granzyme A did not significantly change after treatments, a clear trend of decrease was observed after treatment with Sb + PTX. Interestingly, patients who took longer to heal, regardless of the treatment, displayed a higher frequency of granzyme A cells. Our data suggest that treatment with Sb + PTX acts in CD68 cells reducing the expression of TNF-alpha but not IL-10, resulting in more efficient modulation of the inflammatory response, accelerating the healing process.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0139
2019-06-17
2020-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/2/tpmd190139.html?itemId=/content/journals/10.4269/ajtmh.19-0139&mimeType=html&fmt=ahah

References

  1. Desjeux P, 2004. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305318.
    [Google Scholar]
  2. Oliveira WN, Ribeiro LE, Schrieffer A, Machado P, Carvalho EM, Bacellar O, 2014. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. Cytokine 66: 127132.
    [Google Scholar]
  3. Souza AS, Giudice A, Pereira JM, Guimarães LH, de Jesus AR, de Moura TR, Wilson ME, Carvalho EM, Almeida RP, 2010. Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-α production. BMC Infect Dis 10: 209.
    [Google Scholar]
  4. Gollob KJ, Viana AG, Dutra WO, 2014. Immunoregulation in human American leishmaniasis: balancing pathology and protection. Parasite Immunol 36: 367376.
    [Google Scholar]
  5. Faria DR et al., 2005. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 73: 78537859.
    [Google Scholar]
  6. Bacellar O, Lessa H, Schriefer A, Machado P, De Jesus AR, Dutra WO, Gollob KJ, Carvalho EM, 2002. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 70: 67346740.
    [Google Scholar]
  7. Faria DR, Souza PEA, Durães FV, Carvalho EM, Gollob KJ, MacHado PR, Dutra WO, 2009. Recruitment of CD8+ T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol 31: 432439.
    [Google Scholar]
  8. da Silva Santos C et al., 2013. CD8+GrazymeB+-mediated tissue injury vs. CD4+IFNgamma+-mediated killing in human leishmaniasis. J Invest Dermatol 133: 15331540.
    [Google Scholar]
  9. Cardoso TM, Machado Á, Costa DL, Carvalho LP, Queiroz A, Machado P, Scott P, Carvalho EM, Bacellar O, 2015. Protective and pathological functions of CD8+ T cells in Leishmania braziliensis infection. Infect Immun 83: 898906.
    [Google Scholar]
  10. Novais FO, Scott P, 2015. CD8+ T cells in cutaneous leishmaniasis: the good, the bad and the ugly. Seim Immunopathol 37: 251259.
    [Google Scholar]
  11. Ferraz R, Cunha CF, Pimentel MIF, Lyra MR, Pereira-Da-Silva T, Schubach AO, Da-Cruz AM, Bertho AL, 2017. CD3+CD4negCD8neg (double negative) T lymphocytes and NKT cells as the main cytotoxic-related-CD107a+ cells in lesions of cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Parasit Vectors 10: 219.
    [Google Scholar]
  12. Lessa HA, Machado P, Lima F, Cruz ÁA, Bacellar O, Guerreiro J, Carvalho EM, 2001. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65: 8789.
    [Google Scholar]
  13. Cataldo JI et al., 2018. Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions. Rev Soc Bras Med Trop 51: 769780.Lessa HA, Lessa MM, Guimarães LH, Lima CMF, Arruda S, Machado PR, Carvalho EM, 2012. A proposed new clinical staging system for patients with mucosal leishmaniasis. Trans R Soc Trop Med Hyg 106: 376381.
    [Google Scholar]
  14. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U, 1999. Pentoxifylline inhibits TNF-α production from. Am J Respir Crit Care Med. 159: 508511.
    [Google Scholar]
  15. Machado PRL, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, Carvalho EM, 2007. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44: 788793.
    [Google Scholar]
  16. Brito G, Dourado M, Guimarães LH, Merieles E, Schriefer A, Carvalho EM, Machado PRL, 2017. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for cutaneoul leishmaniasis. Am J Trop Med Hyg 96: 11551159.
    [Google Scholar]
  17. Lessa HA, Lessa MM, Guimarães LH, Lima CMF, Arruda S, Machado PR, Carvalho EM, 2012. A proposed new clinical staging system for patients with mucosal leishmaniasis. Trans R Soc Trop Med Hyg 106: 376381.
    [Google Scholar]
  18. Da-Cruz AM, De Oliveira MP, De Luca PM, Mendonça SC, Coutinho SG, 1996. Tumor necrosis factor-α in human American tegumentary leishmaniasis. Mem Inst Oswaldo Cruz 91: 225229.
    [Google Scholar]
  19. Brito G, Dourado M, Polari L, Celestino D, Carvalho LP, Queiroz A, Carvalho EM, Machado PRL, Passos S, 2014. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 90: 617620.
    [Google Scholar]
  20. Esterre P, Guerret S, Ravisse P, Dimier-David L, Dedet JP, Grimaud JA, 1994. Immunohistochemical analysis of the mucosal lesion in mucocutaneous leishmaniasis. Parasite 1: 305309.
    [Google Scholar]
  21. da Costa DC et al., 2014. Oral manifestations in the American tegumentary leishmaniasis. PLoS One 9: e109790.
    [Google Scholar]
  22. Brunet LR, 2001. Nitric oxide in parasitic infections. Int Immunopharmacol 1: 14571467.
    [Google Scholar]
  23. Bottrel RLA et al., 2001. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble leishmania antigen in human cutaneous leishmaniasis. Infect Immun 69: 32323239.
    [Google Scholar]
  24. Luna T, Santos SB, Nascimento M, Porto MAF, Muniz AL, Carvalho EM, Jesus AR, 2011. Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Braz J Med Biol Res 44: 11341140.
    [Google Scholar]
  25. Ribeiro de Jesus A, Luna T, Pacheco de Almeida R, Machado PRL, Carvalho EM, 2008. Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections. Int Immunopharmacol 8: 13441353.
    [Google Scholar]
  26. Goretsky T, Dirisina R, Sinh P, Mittal N, Managlia E, Williams DB, Posca D, Ryu H, Katzman RB, Barrett TA, 2012. P53 mediates TNF-induced epithelial cell apoptosis in IBD. Am J Pathol 181: 13061315.
    [Google Scholar]
  27. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, Choudhary G, Oezatalay D, Uhal BD, 2000. Apoptosis of lung epithelial cells in response to TNF-α requires angiotensin II generation de novo. J Cell Physiol 185: 253259.
    [Google Scholar]
  28. Chopra DP, Menard RE, Januszewski J, Mattingly RR, 2004. TNF-α-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett 203:145154.
    [Google Scholar]
  29. Miller RA, Britigan BE, 1997. Role of oxidants in microbial pathophysiology. Clin Microbiol Rev 10: 118.
    [Google Scholar]
  30. Anderson P, Nagler-Anderson C, O’Brien C, Levine H, Watkins S, Slayter HS, Blue ML, Schlossman SF, 1990. A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol 144: 574582.
    [Google Scholar]
  31. Trapani JA, Smyth MJ, 2002. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2: 735747.
    [Google Scholar]
  32. Lieberman J, 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3: 361370.
    [Google Scholar]
  33. Fan Z, Zhang Q, 2005. Molecular mechanisms of lymphocyte-mediated cytotoxicity. Cell Mol Immunol 2: 259264.
    [Google Scholar]
  34. Sower LE, Froelich CJ, Allegretto N, Rose PM, Hanna WD, Klimpel GR, 1996. Extracellular activities of human granzyme A. monocyte activation by granzyme A versus alpha-thrombin. J Immunol 156: 25852590.
    [Google Scholar]
  35. Dotiwala F, Mulik S, Polidoro RB, Ansara JA, Burleigh BA, Walch M, Gazzinelli RT, Lieberman J, 2016. Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites. Nat Med 22: 210216.
    [Google Scholar]
  36. Liew FY, Li Y, Millott S, 1990. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145: 43064310.
    [Google Scholar]
  37. de Carsalade GY, Achirafi A, Flageul B, 2003. Pentoxifylline in the treatment of erythema nodosum leprosum. J Dermatol 30: 6468.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0139
Loading
/content/journals/10.4269/ajtmh.19-0139
Loading

Data & Media loading...

  • Received : 14 Feb 2019
  • Accepted : 18 Apr 2019
  • Published online : 17 Jun 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error